Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Drug Interaction of YK-1169 in Healthy Volunteers
NCT05588531Phase 1Completed
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
- Start
- Dec 2021
- Primary completion
- Apr 2022
- Modality
- Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of cefepime + avibactam in bacterial infection and Klebsiella pneumoniae infection (6 arms), sponsored by Nanjing Yoko Biomedical Co., Ltd. Primary endpoints: Adverse Events at 1 month, Body Temperature at 1 month and 3 more. Started Dec 2021; status: completed.
02
Drugs
cefepime + avibactam
03
Conditions
bacterial infectionKlebsiella pneumoniae infection
Beyond the preview
Go deeper on NCT05588531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05588531.